Rodríguez-Covarrubias F, Castillejos-Molina RA, Sotomayor M,Gabilondo F, Feria-Bernal G

Language: English
References: 23
Page: 456-460
PDF size: 53.83 Kb.

ABSTRACT

Objective. To analyze the outcome of patients with clinically localized prostate cancer (PCa) treated with radical prostatectomy (RP) in whom high-grade (HGPCa) and/or locally advanced disease (LAPCa) was found at RP specimen and to evaluate the prognostic value of well-known factors in this subset of patients. Material and methods. Biochemical progression- free (bPFS) was determined with the Kaplan-Meier method. The effect of PSA, biopsy Gleason, clinical stage and number of adverse pathological factors was assessed with univariate and multivariate analyses. Results. After RP, 87 men had HGPCa (20.7%) or LAPCa (56.3%), with 20 (23%) having both criteria. Mean PSA was 15.5 ± 14.0 ng/mL and mean follow-up 50.5 ± 42.6 months. The 5-year bPFS for men with PSA ‹ 10 ng/mL and ≥ 10 ng/mL was 54.7% and 35.7%, respectively (p = 0.03). Regarding biopsy Gleason, the 5-year bPFS was 49% and 26% for patients with a score ≤ 7 and › 7, respectively (p = 0.002). In the multivariate model, the biopsy Gleason score remained independently associated with biochemical progression. Conclusions. HGPCa and/or LAPCa confer poor prognosis; however, RP appears to offer acceptable control, particularly when initial PSA is ‹ 10 ng/mL and biopsy Gleason is 7 or less.

REFERENCES

1. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008; 53: 253-9.

2. Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 2007; 51: 922-9.

3. Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, et al. Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology 2006; 67: 1253-6.

4. Rodríguez-Covarrubias F, Larre S, De La Taille A, Abbou CC, Salomon L. The outcome of patients with pathological Gleason score ≥ 8 prostate cancer after radical prostatectomy. BJU Int 2008; 101: 305-7.

5. Sciarra A, Gentile V, Voria G, Mariotti G, Seccareccia F, Pastore A, et al. Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10. Urol Int 2003; 70: 186-94.

6. Inman BA, DiMarco DS, Slezak JM, Sebo TJ, Kwon ED, Leibovich BC, et al. Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology 2006; 68: 604-8.

7. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005; 95: 751-6.

8. Ward JF, Zincke H. Radical prostatectomy for the patient with locally advanced prostate cancer. Curr Urol Rep 2003; 4: 196- 204.

9. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31.

10. Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20: 3199-205.

11. Rodríguez-Covarrubias F, Castillejos R, Sotomayor M, Gabilondo F, Feria G. The outcome of patients with prostate cancer and adverse pathological characteristics treated with radical prostatectomy. Eur Urol Suppl 2008; 7: 251.

12. Greene FL, Page DL, Fleaming ID, et al. American Joint Committee on Cancer, Manual for staging cancer. New York, NY: Springer; 2002, p. 337.

13. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51.

14. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ Jr, Lilja H, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8.

15. Carroll P, Albertsen PC, Greene K, Babaian RJ, Ballentine Carter H, Gann PH, et al. Prostate specific antigen best practice statement: 2009 update. Available at http://www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines/mainreports/ psa09.pdf

16. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8.

17. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35.

18. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 2002; 167: 117-22.

19. Serni S, Masieri L, Minervini A, Lapini A, Nesi G, Carini M. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology 2006; 67: 373-8.

20. Epstein JI, Carmichael MJ, Partin AW, Walsh PC. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for non-palpable disease: pathogenetic and clinical implications. J Urol 1994; 151: 1587-92.

21. Do TM, Parker RG, Smith RB, Kagan AR. High-grade carcinoma of the prostate: a comparison of current local therapies. Urology 2001; 57: 1121-6.

22. Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Frank I, Blute ML. Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8-10 cancers. BJU Int 2008; 101: 299-304.

23. Katz MH, McKiernan JM. High-risk, clinically localized prostate cancer: is monotherapy adequate? Rev Urol 2007; 9(Suppl. 2): S19-S27.